Literature DB >> 21170298

Ligand Binding Sensitivity of the Extracellular Loop Two of the Cannabinoid Receptor 1.

Alexander C Bertalovitz1, Kwang H Ahn, Debra A Kendall.   

Abstract

The cannabinoid receptor one (CB1) is a class A G-protein-coupled receptor thought to bind ligands primarily within its helical bundle. Evidence suggests, however, that the extracellular domain may also play a role. We have previously shown that the C-terminus of the extracellular loop 2 of CB1 is important in binding some compounds; receptors with mutations in this region (F268W, P269A, H270A, and I271A) bound some agonists with severely reduced affinity relative to the wild-type receptor. In the present work, we examine the impact of these mutations on binding a chemically diverse set of ligands. The receptors, F268W and I271A, exhibited a greater sensitivity to binding the inverse agonists/antagonists SLV319, AVE1625, NESS0327 relative to P269A and H270A, suggesting that the Pro and His are not involved in binding those compounds. In contrast, binding of the agonists, BAY593074 and WIN55212-2, was diminished in all four receptors, suggesting the conformational unit contributed by all four residues is important. A more marked loss in binding was observed for agonists of the nonclassical (CP55940) and classical (HU-210, JWH061, JWH179) cannabinoid classes and for a silent antagonist derivative (O-2050), pointing to the critical nature of this region for binding both the bicyclic/tricyclic core and the alkyl chain of these derivatives. However, moving the location of the alkyl chain on a series of pyrazole analogues shows it can be better accommodated in certain locations (O-1255) than others (O-1302, O-1690) and underscores the involvement of residues F268 and I271.

Entities:  

Year:  2010        PMID: 21170298      PMCID: PMC3003262          DOI: 10.1002/ddr.20388

Source DB:  PubMed          Journal:  Drug Dev Res        ISSN: 0272-4391            Impact factor:   4.360


  36 in total

Review 1.  Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors.

Authors:  Patricia H Reggio
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

Review 2.  How many drug targets are there?

Authors:  John P Overington; Bissan Al-Lazikani; Andrew L Hopkins
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

3.  Ligand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor.

Authors:  Hamiyet Unal; Rajaganapathi Jagannathan; Manjunatha B Bhat; Sadashiva S Karnik
Journal:  J Biol Chem       Date:  2010-03-18       Impact factor: 5.157

4.  Cysteine residues in the human cannabinoid receptor: only C257 and C264 are required for a functional receptor, and steric bulk at C386 impairs antagonist SR141716A binding.

Authors:  Jonathan F Fay; Thomas D Dunham; David L Farrens
Journal:  Biochemistry       Date:  2005-06-21       Impact factor: 3.162

5.  Determination and characterization of a cannabinoid receptor in rat brain.

Authors:  W A Devane; F A Dysarz; M R Johnson; L S Melvin; A C Howlett
Journal:  Mol Pharmacol       Date:  1988-11       Impact factor: 4.436

6.  Molecular characterization of a peripheral receptor for cannabinoids.

Authors:  S Munro; K L Thomas; M Abu-Shaar
Journal:  Nature       Date:  1993-09-02       Impact factor: 49.962

7.  Dual role of the second extracellular loop of the cannabinoid receptor 1: ligand binding and receptor localization.

Authors:  Kwang H Ahn; Alexander C Bertalovitz; Dale F Mierke; Debra A Kendall
Journal:  Mol Pharmacol       Date:  2009-07-30       Impact factor: 4.436

8.  Phenylalanine 169 in the second extracellular loop of the human histamine H4 receptor is responsible for the difference in agonist binding between human and mouse H4 receptors.

Authors:  Herman D Lim; Aldo Jongejan; Remko A Bakker; Eric Haaksma; Iwan J P de Esch; Rob Leurs
Journal:  J Pharmacol Exp Ther       Date:  2008-07-17       Impact factor: 4.030

9.  An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region.

Authors:  Sean D McAllister; Gulrukh Rizvi; Sharon Anavi-Goffer; Dow P Hurst; Judy Barnett-Norris; Diane L Lynch; Patricia H Reggio; Mary E Abood
Journal:  J Med Chem       Date:  2003-11-20       Impact factor: 7.446

Review 10.  Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.

Authors:  David R Janero; Alexandros Makriyannis
Journal:  Expert Opin Emerg Drugs       Date:  2009-03       Impact factor: 4.191

View more
  11 in total

Review 1.  New Insights in Cannabinoid Receptor Structure and Signaling.

Authors:  Lingyan Ye; Zheng Cao; Weiwei Wang; Naiming Zhou
Journal:  Curr Mol Pharmacol       Date:  2019       Impact factor: 3.339

Review 2.  New paradigms in chemokine receptor signal transduction: Moving beyond the two-site model.

Authors:  Andrew B Kleist; Anthony E Getschman; Joshua J Ziarek; Amanda M Nevins; Pierre-Arnaud Gauthier; Andy Chevigné; Martyna Szpakowska; Brian F Volkman
Journal:  Biochem Pharmacol       Date:  2016-04-19       Impact factor: 5.858

3.  Allosteric modulators restore orthosteric agonist binding to mutated CB1 receptors.

Authors:  Rachel Dopart; Debra A Kendall
Journal:  J Pharm Pharmacol       Date:  2019-11-13       Impact factor: 3.765

4.  Crystal Structure of the Human Cannabinoid Receptor CB1.

Authors:  Tian Hua; Kiran Vemuri; Mengchen Pu; Lu Qu; Gye Won Han; Yiran Wu; Suwen Zhao; Wenqing Shui; Shanshan Li; Anisha Korde; Robert B Laprairie; Edward L Stahl; Jo-Hao Ho; Nikolai Zvonok; Han Zhou; Irina Kufareva; Beili Wu; Qiang Zhao; Michael A Hanson; Laura M Bohn; Alexandros Makriyannis; Raymond C Stevens; Zhi-Jie Liu
Journal:  Cell       Date:  2016-10-20       Impact factor: 41.582

5.  Novel insights into CB1 cannabinoid receptor signaling: a key interaction identified between the extracellular-3 loop and transmembrane helix 2.

Authors:  Jahan Marcu; Derek M Shore; Ankur Kapur; Megan Trznadel; Alexandros Makriyannis; Patricia H Reggio; Mary E Abood
Journal:  J Pharmacol Exp Ther       Date:  2013-02-20       Impact factor: 4.030

6.  Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling.

Authors:  Derek M Shore; Gemma L Baillie; Dow H Hurst; Frank Navas; Herbert H Seltzman; Jahan P Marcu; Mary E Abood; Ruth A Ross; Patricia H Reggio
Journal:  J Biol Chem       Date:  2013-12-23       Impact factor: 5.157

7.  Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands.

Authors:  Evangelia Kotsikorou; Haleli Sharir; Derek M Shore; Dow P Hurst; Diane L Lynch; Karla E Madrigal; Susanne Heynen-Genel; Loribelle B Milan; Thomas D Y Chung; Herbert H Seltzman; Yushi Bai; Marc G Caron; Larry S Barak; Mitchell P Croatt; Mary E Abood; Patricia H Reggio
Journal:  Biochemistry       Date:  2013-12-17       Impact factor: 3.162

8.  Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent Behavior.

Authors:  Miriam Schneider; Fernando Kasanetz; Diane L Lynch; Chris M Friemel; Olivier Lassalle; Dow P Hurst; Frauke Steindel; Krisztina Monory; Carola Schäfer; Isabelle Miederer; F Markus Leweke; Mathias Schreckenberger; Beat Lutz; Patricia H Reggio; Olivier J Manzoni; Rainer Spanagel
Journal:  J Neurosci       Date:  2015-10-14       Impact factor: 6.167

9.  Probing the carboxyester side chain in controlled deactivation (-)-δ(8)-tetrahydrocannabinols.

Authors:  Spyros P Nikas; Rishi Sharma; Carol A Paronis; Shashank Kulkarni; Ganesh A Thakur; Dow Hurst; JodiAnne T Wood; Roger S Gifford; Girija Rajarshi; Yingpeng Liu; Jimit Girish Raghav; Jason Jianxin Guo; Torbjörn U C Järbe; Patricia H Reggio; Jack Bergman; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2014-12-16       Impact factor: 7.446

Review 10.  Cannabinoid1 (CB-1) receptor antagonists: a molecular approach to treating acute cannabinoid overdose.

Authors:  Phil Skolnick; Roger Crystal
Journal:  J Neural Transm (Vienna)       Date:  2019-12-31       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.